A Pharmacokinetic Study of JS002 in Healthy Subjects

Phase 1

Active, not recruiting

• Conditions: Health Volunteer
• Interventions: Drug: JS002

• Registration Number: NCT05859529
• Lead Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Brief Summary

This study was a single-center, randomized, open-label, single-dose, parallel-controlled trial design conducted in healthy adult subjects. Subjects were randomly assigned to 1 of 2 parallel treatment groups: treatment group A received a single subcutaneous injection of JS002 150 mg via PFS, and treatment group B received a single subcutaneous injection of JS002 150 mg via AI. Subjects were followed up to study day 85 for pharmacokinetic equivalence assessment of JS002. A total of 159 subjects were planned to be included in each group. After signing the informed consent form and completing the screening examination, subjects will be randomly assigned to treatment arm A or treatment arm B if eligible for inclusion.

The study period consisted of a screening period of up to 21 days and a follow-up period of 12 weeks (85 days). Subjects were admitted to the phase I clinical research unit the day before dose administration (day 1) and were not allowed to leave until all examinations and assessments were completed on day 6 after dose administration and were allowed to return to the clinical research center for follow-up visits on days 8,11,15,22,29,43,57,71, and 85.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-04-23
• Study First Submitted QC: 2023-05-15
• Study First Posted: 2023-05-16
• Study Start: 2023-05-30
• Status Verified: 2023-06
• Last Update Submitted: 2023-06-24
• Last Update Posted: 2023-06-27
• Primary Completion: 2023-06-30
• Study Completion: 2023-12-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 318

Inclusion Criteria

1. Healthy male or female volunteers aged 18-45 years at screening;
2. have the ability to read and understand, voluntarily participate in the study, sign the written informed consent, and be able to complete the relevant procedures and examinations in accordance with the protocol;
3. the body mass index (BMI) at screening ranged from 19 to 26 kg/m2 (inclusive), with body weight ≥50kg for men and ≥45kg for women;
4. sitting blood pressure ≥ 90/60mmHg and < 140/90mmHg during screening;
5. serum LDL-C level ≥1.8mmol/L and < 4.9mmol/L at screening;
6. serum TG level < 2.8mmol/L at screening;
7. infertile, or fertile women willing to use strict and effective contraceptive methods throughout the study, in addition, fertile female subjects should have negative blood pregnancy test results during the screening period.

Exclusion Criteria

1. Any history of use of Evolocumab and/or Alirocumab and other targeted drugs against PCSK9;
2. Use of any therapeutic or investigational biologics within 6 months before baseline (day 1);
3. Use of any medications or supplements that can alter blood lipids or affect lipid metabolism within 30 days before baseline (day 1), including but not limited to: Statins (such as atorvastatin, rosuvastatin, etc.), cholesterol absorption inhibitors (such as ezetimibe), probucol, cholic acid chelators (such as cholestyramine), traditional Chinese medicine (such as Xuezhikang), fibrates, high-purity fish oil preparations (or omega-3 fatty acids 1000 mg/ day), niacin preparations (niacin > 50 mg), etc.
4. Initiation of new vigorous exercise (e.g., long-distance running) or dietary control, or major modification of previous diet or lifestyle (e.g., exercise, smoking, and alcohol consumption) within 30 days before baseline (day 1). Creatine kinase (CK) ≥3 times the upper limit of normal value (ULN) on the day before randomization (day-1);
5. A history of allergy to biologics of mammalian origin (including monoclonal antibodies);
6. Subjects with allergic diseases or allergic constitution;
7. Patients with definite diseases of the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, endocrine system, and metabolic system that require medical intervention or other diseases that are not suitable for clinical trial (such as psychiatric history);
8. Donating ≥400 mL within 3 months before screening, or donating ≥200 mL within 1 month before screening, or receiving blood transfusion;
9. Participants who participated in other drug clinical trials within 3 months before screening;
10. Those who had taken any prescription drugs, over-the-counter drugs, herbal medicines, or health supplements within 2 weeks before screening;
11. Heavy smokers and drinkers (drinking 14 units of alcohol per week:1unit = beer 360 mL, or liquor 45 mL, or wine 150 mL; Smoking ≥5 cigarettes per day), or unable to abstain from smoking or drinking alcohol during the study period;
12. Had a history of drug abuse, or used drugs within 3 months before screening, or had a positive urine drug screening test during the screening period;
13. Hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (Anti-HCV), treponema pallidum antibody and acquired immunodeficiency syndrome (HIV) antibody positive;
14. Abnormal chest X-ray (posterior-anterior view) and abdominal B-ultrasound results with clinical significance (non-clinically significant conditions such as irritability of gallbladder wall, hepatic cysts, intrahepatic calcifications, intrahepatic bile duct stones, slight fatty liver, etc., should be excluded).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental：JS002 AI	JS002	The drug was administered by a single subcutaneous injection via AI
Experimental：JS002 PFS	JS002	The drug was administered by a single subcutaneous injection via PFS

Primary Outcome Measures

Name	Time	Method
Cmax	85 days	Maximum Concentration
AUC0-last	85 days	Area under the time-concentration curve from time 0 to last time of quantifiable concentration

Secondary Outcome Measures

Name	Time	Method
CL/F	85 days	Apparent clearance
t1/2	85 days	Elimination half life
Incidence of Treatment-Emergent Adverse Events	85 days	Incidence and severity of adverse events (AE) and serious adverse events (SAE) as assessed according to NCI-CTCAE 5.0, as well as abnormalities in physical examination, vital signs, electrocardiogram, laboratory tests.
Tmax	85 days	Time to reach maximum concentration
Vz/F	85 days	Apparent volume of distribution
AUECday1-85	85 days	Area under the effect curve (AUEC) for LDL-C through Day 1 to day 85
PCSK9	85 days	Serum concentration of PCSK9
Immunogenicity	85 days	Titer of ADA-positive samples, and incidence of neutralizing antibodies (Nab)

Trial Locations

Locations (1)

Shenzhen Third People's Hospital; 🇨🇳 Shenzhen, Guangdong, China